Sanofi type 2 diabetes new drug is approved by the US FDA today
Sanofi type 2 diabetes new drug is approved by the US FDA today August 03, 2016 Source: WuXi PharmaTech Today, Sanofi's Adlyxin (lixisenatide) is approved by the US FDA. This combination of daily doses of new drugs, combined with diet and exercise, can effectively improve blood sugar levels in adult patients with type 2 diabetes. Diabetes is a chronic disease that has a large number of patients and seriously affects the health of patients. According to the World Health Organization's report in April this year, there are more than 400 million people with diabetes worldwide, and one in four of them are in China, which means that hundreds of millions of Chinese adults have diabetes! If the condition is not effectively controlled, diabetes can have a huge impact on the health of the patient - these patients will have a sharp increase in the risk of heart disease or stroke, as well as diabetic retinopathy, renal failure, foot neuropathy, amputation, etc. as a result of. Type 2 diabetes accounts for nearly 90% of all diabetes cases. Cells in patients with type 2 diabetes tend to be insensitive to insulin, causing a decline in glucose absorption and storage, and an increase in blood sugar. Currently, the standard treatment for these patients is to perform frequent insulin injections to increase the concentration of insulin in the blood. Of course, this will lead to common problems such as pain and the daily life of the patient. Sanofi's Adlyxin (lixisenatide) is expected to be another effective treatment for patients with type 2 diabetes. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that promotes insulin secretion and synthesis, inhibits glucagon release after meals, delays gastric emptying, improves beta cell function, and prevents apoptosis. It plays a wide range of hypoglycemic effects by multiple actions. The safety and efficacy of the drug was evaluated in 5400 patients with type 2 diabetes in 10 clinical trials. In these trials, Adlyxin was compared as an independent therapy with other FDA-approved diabetes drugs such as metformin, sulfonylureas, pioglitazone or basal insulin. The results showed that lixisenatide only needs to be injected once a day, which can effectively reduce the patient's blood sugar level and is well tolerated. Lixisenatide has been approved in more than 40 markets worldwide using the proprietary trade name Lyxumia, including most EU countries, Japan, Brazil, Mexico and India. Dr. Mary Thanh Hai Parks, deputy director of the Drug Evaluation Office of the FDA's Center for Drug Evaluation and Research, said: "The US FDA will continue to support the development of new drugs for managing diabetes. Adlyxin will increase the availability of practical treatment options for patients with type 2 diabetes to control blood sugar. Level. Smart Door Lock,Smart Locks,Smart Locks For Home,Intelligent Lock Zhejiang Tilanco Industry&Trade Group Co., Ltd , https://www.tilancogroup.com